Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The first patient has been treated in a first-in-human clinical trial investigating the safety and efficacy of the CXLens system, a quantitative corneal cross-linking, or qCXL, technology for noninvasive refractive vision correction.
“This milestone represents the beginning of a new era in vision correction,” Thomas Dunlap, CEO of TECLens, told Healio. “For decades, refractive procedures have relied on removing or reshaping tissue through surgery. With qCXL, we are taking a fundamentally different approach — strengthening the cornea to reshape it, without cutting or compromising its